Nurix Therapeutics (NRIX) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
UroGen Pharma (URGN) has outperformed Nurix Therapeutics (NRIX) over the past year, gaining 6.9% versus a loss of 23.3%. Over five years, URGN leads with a +127.8% price change compared with -57.3% for NRIX. Nurix Therapeutics is the larger company by market cap ($1.40 billion vs $1.36 billion), about 1.0 times the size.
UroGen Pharma converts more of its revenue into profit, with a net margin of -139.8% versus -314.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRIX | URGN |
|---|---|---|
| Share price | $12.85 | $27.65 |
| Market cap | $1.40B | $1.36B |
| 1-day change | -5.55% | -12.86% |
| YTD return | -32.26% | +18.06% |
| 1-year return | -23.33% | +6.88% |
| 5-year return | -57.25% | +127.76% |
| P/E ratio (TTM) | 5.29 | — |
| Forward P/E | — | 11.08 |
| EPS (TTM) | $2.43 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $83.98M | $109.79M |
| Revenue growth (YoY) | +53.95% | +21.45% |
| Net income (latest FY) | $-264.46M | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | -340.16% | -113.73% |
| Net margin | -314.90% | -139.81% |
| 52-week high | $28.23 | $50.81 |
| 52-week low | $12.83 | $16.50 |
| Distance from 52-week high | -54.50% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +160.80% | +119.57% |
| Average volume | 2.47M | 1.11M |
| Shares outstanding | 109.25M | 49.05M |
| Employees | 317 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed NRIX by 30.2 percentage points over the past year.
- UroGen Pharma is more profitable, keeping -139.8 cents of every revenue dollar as net income versus -314.9 cents for Nurix Therapeutics.
- Nurix Therapeutics grew revenue faster in its latest fiscal year (+53.95% vs +21.45%).
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
NRIX vs URGN FAQ
Which is bigger, Nurix Therapeutics or UroGen Pharma?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $1.40B compared with $1.36B for UroGen Pharma (URGN).
Which stock has performed better over the past year, NRIX or URGN?
URGN returned +6.88% over the past 12 months, compared with -23.33% for NRIX (price return, excluding dividends). Past performance does not predict future results.
Are Nurix Therapeutics and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.